| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 8 | — | 17.3x | Bottom tier | |
Growth | 77 | 158.9% | 7.1% | Top tier | |
Quality | 44 | -30.0% | 4.4% | Around median | |
Safety | 58 | — | 2.6x | Around median | |
Capital Return | 10 | 0.00% | 0.06% | Bottom tier | |
Momentum | 34 | -20.7% | -1.7% | Bottom tier | |
Sentiment | 46 | 12 | 3 | Around median |
10-year US Treasury yield 5.00% as of 2026-10-23. Estimates computed from company data and analyst targets, not investment advice.
Beam Therapeutics Inc. is a clinical-stage biotechnology company developing genetic medicines based on base editing, a form of CRISPR that changes individual DNA bases without causing double-strand breaks. Its economic thesis relies on converting its platform and liver delivery via lipid nanoparticles into single-dose therapies, and its portfolio includes risto-cel for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-301 for glycogen storage disease type Ia, and BEAM-304 for phenylketonuria. Management confirmed during the fiscal year 2025 quarter 4 call that the pipeline is wholly owned by the company.
In fiscal year 2026 quarter 2, Beam recorded revenue of $0.49 million and a net loss of $122.7 million, equivalent to a loss of $1.18 per share. This represents a sharp decline in revenue from $31.7 million in fiscal year 2026 quarter 1, while the quarterly loss widened from $94.3 million, reflecting the investment case's continued reliance on clinical and regulatory program progress rather than current profitability.
Latest twelve-month revenue reached $156.0 million, versus a net loss of $85.4 million and a loss of approximately $0.82 per share, after the company recorded fiscal year 2025 revenue of $139.7 million and a net loss of $80.0 million. Beam ended 2025 with $1.25 billion in cash, cash equivalents, and marketable securities, and management said on February 24, 2026, that the Sixth Street facility and expected payments from it extend the projected cash runway to mid-2029.
Automated analysis for informational purposes only — not investment advice.
The average analyst target is $59.5, within a wide range of $39 to $80, with a “Buy” consensus; the average is approximately 55.5% above the 52-week range high of $38.26, while the lowest target is only approximately 1.9% above it. No positive price-to-earnings ratio is available because of the losses, so valuation is based primarily on the programs' probabilities of success, while the breadth of the target range reflects high uncertainty regarding the timing of approvals and the commercial value of risto-cel, BEAM-302, and BEAM-304.
Figures in the text are as of 2026-08-31; the live price is shown at the top of the page.
Beam uses base editing to make precise changes to individual DNA bases without causing double-strand breaks. Its liver programs combine this technology with lipid nanoparticles that can be administered through intravenous infusion, and the company says they can be adjusted and redosed when needed. In BEAM-304, the guide RNA changes according to the PKU mutation, while the remaining treatment components stay largely similar.
BEAM-304 targets phenylketonuria, which affects approximately 20,000 people in the United States according to the February 24, 2026 presentation. The company identified candidates for the first two mutations, including R408W, that together could cover approximately half of patients. In two mouse models, a single dose of 0.3 mg per kg reduced phenylalanine to below the therapeutic threshold by day 7, and Beam plans to submit an application to begin the clinical study during 2026.
Management expects to update phase 1/2 data and define the pivotal steps for BEAM-302 during 2026. It also aims to submit the biologics license application for risto-cel as early as the end of 2026 and to submit an application to begin the clinical study for BEAM-304 in the same year. The plan also includes initial data for BEAM-301, completion of the healthy-volunteer study for BEAM-103, and continued development of in vivo hematopoietic stem cell editing.
Beam ended 2025 with $1.25 billion in cash, cash equivalents, and marketable securities. The Sixth Street agreement provides up to $500 million, including $100 million at closing, up to $300 million upon achieving risto-cel milestones, and an additional $100 million subject to mutual approval. Including an expected minimum draw of $200 million, management expects the cash runway to extend to mid-2029, while the financing principal matures in early 2033.
In fiscal year 2026 quarter 2, revenue was $0.49 million and net loss was $122.7 million, or $1.18 per share. In fiscal year 2026 quarter 1, revenue was $31.7 million and net loss was $94.3 million, highlighting the revenue decline and widening loss between the two periods. On a latest twelve-month basis, the company recorded revenue of $156.0 million and a net loss of $85.4 million.
The analyst consensus is “Buy,” with an average target of $59.5 within a range of $39 to $80. The average target is approximately 55.5% above the 52-week range high of $38.26, but the breadth of the targets reflects substantial differences in assessments of the clinical programs' risks. In insider activity, net selling reached $12.2 million across eight sales during the three months through July 27, 2026, with no purchases, though this should be treated as a limited signal because the sales may be prearranged.